TrialStem cell research & therapy2026

Safety and feasibility of intravenous fresh adipose-derived mesenchymal stem cells in secondary progressive multiple sclerosis: phase I/IIa clinical results.

Fahimeh Lavi Arab et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.